{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:53:27Z","timestamp":1768550007164,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03360-9","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T08:04:01Z","timestamp":1664438641000},"page":"953-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-0203","authenticated-orcid":false,"given":"Marisa","family":"Rold\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Escoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hern\u00e2ni","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Vila","family":"Lobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"3360_CR1","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/ndt\/gft338","volume":"28","author":"R Minutolo","year":"2013","unstructured":"Minutolo R, Locatelli F, Gallieni M et al (2013) Anaemia management in non-dialysis chronic kidney dis-ease (CKD) patients: a multicenter prospective study in renal clinics. Nephrol Dial Transpl 28:3035\u20133045","journal-title":"Nephrol Dial Transpl"},{"key":"3360_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/ckj\/sfx060","volume":"11","author":"AG Stack","year":"2017","unstructured":"Stack AG, Alghali A, Li X et al (2017) Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J 11:99\u2013107","journal-title":"Clin Kidney J"},{"key":"3360_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","volume":"6","author":"JL Babitt","year":"2021","unstructured":"Babitt JL, Eisenga MF, Haase VH et al (2021) Controversies in optimal anemia management: conclusion from a Kidney Disease: improving Global Outcomes (KDIGO) Conference. Kidney Int 6:1280\u20131295","journal-title":"Kidney Int"},{"key":"3360_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279\u2013335","journal-title":"Kidney Int Suppl"},{"key":"3360_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A et al (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transpl 28:1346\u20131359","journal-title":"Nephrol Dial Transpl"},{"key":"3360_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi WY, Martinez C, Smith M et al (2011) A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transpl 26:1599\u20131607","journal-title":"Nephrol Dial Transpl"},{"key":"3360_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/ndt\/gfs528","volume":"28","author":"C Charytan","year":"2013","unstructured":"Charytan C, Bernardo MV, Koch TA et al (2013) Intravenous ferric carboxy maltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transpl 28:953\u2013964","journal-title":"Nephrol Dial Transpl"},{"key":"3360_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, FIND-CKD Study Investigators et al (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:2075\u20132084","journal-title":"Nephrol Dial Transplant"},{"key":"3360_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ki.2015.163","volume":"88","author":"R Agarwal","year":"2015","unstructured":"Agarwal R, Kusek JW, Pappas MK (2015) A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88:905\u2013914","journal-title":"Kidney Int"},{"key":"3360_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.tcb.2006.12.003","volume":"17","author":"LL Dunn","year":"2007","unstructured":"Dunn LL, Rahmanto YS, Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol 17:93\u2013100","journal-title":"Trends Cell Biol"},{"issue":"Suppl 2","key":"3360_CR11","doi-asserted-by":"publisher","first-page":"568S","DOI":"10.1093\/jn\/131.2.568S","volume":"131","author":"JL Beard","year":"2001","unstructured":"Beard JL (2001) Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 131(Suppl 2):568S-579S","journal-title":"J Nutr"},{"key":"3360_CR12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Colet JC, Filippatos G, FAIR-HF Trial Investigators et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436\u20132448","journal-title":"N Engl J Med"},{"key":"3360_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ejhf.229","volume":"17","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, Filippatos G, Colet JC, FAIR-HF Trial Investigators et al (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17:329\u2013339","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"3360_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ndt\/gfaa088","volume":"36","author":"R Minutolo","year":"2021","unstructured":"Minutolo R, Garofalo C, Chiodini P et al (2021) Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrol Dial Transpl 36(2):267\u2013274","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"3360_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ki.2011.49","volume":"80","author":"SL Seliger","year":"2011","unstructured":"Seliger SL, Zhang AD, Weir MR et al (2011) Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 80(3):288\u2013294","journal-title":"Kidney Int"},{"key":"3360_CR16","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/j.1523-1755.2004.00648.x","volume":"65","author":"R Agarwal","year":"2004","unstructured":"Agarwal R, Vasavada N, Sachs NG et al (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279\u20132289","journal-title":"Kidney Int"},{"issue":"6","key":"3360_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3390\/jcm10061322","volume":"10","author":"R Minutolo","year":"2021","unstructured":"Minutolo R, Berto P, Liberti ME et al (2021) Ferric carboxymaltose in non-hemodialysis CKD patients: a longitudinal cohort study. J Clin Med 10(6):1322","journal-title":"J Clin Med"},{"key":"3360_CR18","first-page":"345","volume":"60","author":"F Funk","year":"2010","unstructured":"Funk F, Ryle P, Canclini C et al (2010) The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 60:345\u2013353","journal-title":"Arzneimittelforschung"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03360-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:12:34Z","timestamp":1679404354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["3360"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03360-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}